Novo Nordisk starts Ph II on DRF-2725
After Novartis pulled out of a North American co-development deal onthe Dr Reddy's Laboratories-originated non-insulin dependent diabetes 2 therapy DRF-2725 (NN622) with Novo Nordisk (Marketletter November 5), the latter has taken the drug into Phase III trials. This move, as originally planned, has triggered a first (undisclosed) milestone payment to Dr Reddy's, the Indian company has announced.
DRF-2725 (NN622) is a peroxisome proliferator-activated receptor alpha and gamma agonist which, according to Dr Reddy's, in pre- and early-clinical trials and in clinical proof-of-concept studies has shown potential to regulate these parameters and thereby blood glucose and diabetic dysplasia.
The compound is chemically and pharmacologically different from presently-marketed PPAR agonists and constitutes a new class of insulin sensitizers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze